WallachBeth Capital Upgrades DepoMed Inc (DEPO) to Buy

Go back to WallachBeth Capital Upgrades DepoMed Inc (DEPO) to Buy

Depomed (DEPO) Tops Q3 EPS by 14c

November 9, 2015 4:04 PM EST

Depomed (NASDAQ: DEPO) reported Q3 EPS of $0.33, $0.14 better than the analyst estimate of $0.19. Revenue for the quarter came in at $105 million versus the consensus estimate of $101.64 million.

Opportunities for Sustained Growth·

NUCYNTA is strongly positioned... More